Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 28, 2025 09:05 ET | Source: Sonnet BioTherapeutics Holdings, Inc.

Sonnet BioTherapeutics Further Expands Global Intellectual Property Portfolio with Issuance of EU Patent for FHAB® Platform Technology

European Patent Office (EPO) grants EU Patent No. EP3583125 B1 covering the Company’s Fully Human Albumin Binding (FHAB®) domain fusion proteins In addition to the U.S. and EU, Sonnet’s global IP...